Reports
Sale
Osteoporosis Market Size, Share, Trends, Analysis, Forecast: By Type: Primary Osteoporosis, Secondary Osteoporosis; By Therapy: Bisphosphonates, Selective Estrogen Receptor Modulators, Parathyroid Hormone Therapy, Others; By Route of Administration; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Osteoporosis Market Outlook
The osteoporosis market size in the 7 major markets was valued at USD 13.9 billion in 2023, driven by increasing innovations and research activities. The market size is anticipated to grow at a CAGR of 3.58% during the forecast period of 2024-2032 to achieve a value of USD 19.9 billion by 2032.
Osteoporosis Market Overview
Osteoporosis can be characterized by low bone mass, deterioration of bone tissue, bone sterility, and constant risk of fracturing the bones. The most common cause of a broken bone among the elderly is osteoporosis. Bones that are most affected by the condition include the vertebrae in the spine, forearm, the wrist, and the hip. This condition typically exhibits no symptoms until it is diagnosed during the examination of a fractured bone. It makes it hard for the patients to carry out regular daily life activities as a little amount of pressure or stress may result in a broken bone.
The development of new, more effective osteoporosis medications, and advancements in bone density testing, is also driving the osteoporosis market growth. Government support and initiatives aimed at improving bone health and lowering the incidence of osteoporosis-related fractures are also fuelling the market growth.
Prevalence of Osteoporosis to Drive the Market Growth
The market is expected to witness significant growth driven by the increase in the incidence of osteoporosis. According to the International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures annually, resulting in a fracture every three seconds around the world. The market growth can be further attributed to the growing investment in research and development activities conducted by biotechnology and pharmaceutical companies. The increasing public awareness of the condition is also playing a crucial role in the increasing number of diagnoses, contributing to the osteoporosis market share. Moreover, the market is expected to be driven by the rising technological advancements and drug development, likely to bolster the market growth during the forecast period.
Innovations Expected to Bolster Market Growth
The market is expected to witness significant growth driven by ground-breaking innovations and developments in the forecast period. For instance, in June 2023, the development of a robotic pill that safely delivers injectable osteoporosis drugs. The highly encouraging efficacy has offered hope to individuals suffering from chronic conditions, such as osteoporosis, as the only route of administration currently available is painful injections. This pioneering technology has the potential to revolutionize treatment options for patients, providing a painless alternative to injections.
Technical Advancements to Bolster the Demand
The market growth is expected to be driven by the new technologically advanced developments, exemplified by the development of OsteoBoost by Bone Health Technologies. It is a vibration belt designed to fight osteoporosis and osteopenia. OsteoBoost has been developed on 15 years of published research, including research from NASA. Bone Health Technologies has filed for Class 2 Prescription De Novo Approval with the FDA. Such developments attract investors which plays a crucial role in the market development and stability, likely to aid the osteoporosis market size in the forecast period.
Government Initiatives to Aid the Growth
Additionally, increasing initiatives and efforts by non-government organizations towards creating awareness and providing solutions are collectively contributing to osteoporosis market growth. For instance, in Feb 2023, the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) signed an agreement to develop a strategic roadmap on bone health and aging and advocate for a public health strategy to prevent fractures among older people. This partnership with WHO is expected to enhance the prevention and management of osteoporosis at local, regional, and national levels resulting in an enhanced quality of life for individuals living with this condition.
Increasing Research and Clinical Trials Leading New Opportunities
The increasing number of clinical trials to examine the efficacy of a drug is a major factor responsible for the growth of the osteoporosis market value. In May 2023, new research showed how women taking romosozumab, a new anti-osteoporosis drug available on the NHS, might be at risk of a heart attack. The University of Bristol-led study analysed the genetic data on about 34,000 people. Romosomuzab is an effective medicine prescribed to women with severe osteoporosis to reduce the risk of fracture. Discoveries like this are expected to spark discussion among healthcare professionals and researchers to perform more research and find the truth. Additionally, it sparks competition in the market as it brings opportunities for pharmaceutical companies to develop more suitable drugs with no side effects and high efficacy, boosting the market size.
Osteoporosis Market Segmentations
Market Breakup by Type
- Primary Osteoporosis
- Secondary Osteoporosis
Market Breakup by Therapy
- Bisphosphonates
- Selective Estrogen Receptor Modulators
- Parathyroid Hormone Therapy
- RANK Ligand Inhibitors
Market Breakup by Route of Administration
- Oral
- Injectable
- Others
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Market Breakup by Distribution Channel
- Hospitals
- Retail Pharmacies
- Online Pharmacies
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Osteoporosis Market Analysis
The United States is dominating the market and is expected to continue dominating the market during the forecast period driven by the presence of key players and the high prevalence of osteoporosis patients in the region. The presence of a robust and high-tech healthcare infrastructure, coupled with the availability of advanced drugs, is expected to drive the osteoporosis market growth.
In November 2023, Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced the approval of a generic version of Forteo in the United States. Teva's generic equivalent of Forteo (teriparatide injection) utilizes the Antares Pharma, Inc. multi-dose pen device. Teriparatide injection is indicated to treat osteoporosis among certain women and men. Such announcements indicate more affordable options becoming available for treating osteoporosis and accessible to people in need. More affordable options can potentially increase access to osteoporosis treatment, leading to growing demand for these medications.
Osteoporosis Market: Competitor Landscape
In May 2023, Amgen announced that Prolia® (denosumab) injection has been found effective in reducing the risk of fractures in postmenopausal women compared to a common pill treatment called oral alendronate. The announcement was based on new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program. The treatment was also associated with greater reductions in fracture risk over time. Consequentially, doctors and patients are expected to prefer Prolia due to the promising long-term results. This announcement could also encourage further research and development of similar treatments, making more options available to help manage osteoporosis effectively.
The key features of the osteoporosis market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- DAIICHI SANKYO COMPANY
- Amgen Inc.
- Merck & Co., Inc
- AbbVie Inc
- Bayer AG
- Johnson & Johnson Services, Inc.
- Sanofi.
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
- Astrazeneca
- Eli Lilly And Company
- Novartis AG
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc.
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Therapy |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Osteoporosis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Osteoporosis Epidemiology Analysis-Seven Major Markets
5.1 Epidemiology Overview (2017-2032)
5.2 7MM Epidemiology Scenario Overview (2017-2032)
5.3 United States Osteoporosis Epidemiology Forecast (2017-2032)
5.4 EU-4 and United Kingdom Osteoporosis Epidemiology Forecast (2017-2032)
5.4.1 Germany Osteoporosis Epidemiology Forecast (2017-2032)
5.4.2 France Osteoporosis Epidemiology Forecast (2017-2032)
5.4.3 Italy Osteoporosis Epidemiology Forecast (2017-2032)
5.4.4 Spain Osteoporosis Epidemiology Forecast (2017-2032)
5.4.5 United Kingdom Osteoporosis Epidemiology Forecast (2017-2032)
5.5 Japan Osteoporosis Epidemiology Forecast (2017-2032)
6 Osteoporosis Market Overview- Seven Major Markets
6.1 Osteoporosis Market Historical Value (2017-2023)
6.2 Osteoporosis Market Forecast Value (2024-2032)
7 Osteoporosis Market Landscape- Seven Major Markets
7.1 Osteoporosis Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Osteoporosis Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Therapy
7.2.3 Analysis by Route of Administration
8 Osteoporosis Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Osteoporosis Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Osteoporosis Market Segmentation- Seven Major Markets
11.1 Osteoporosis Market by Type
11.1.1 Market Overview
11.1.2 Primary Osteoporosis
11.1.3 Secondary Osteoporosis
11.2 Osteoporosis Market by Therapy
11.2.1 Market Overview
11.2.2 Bisphosphonates
11.2.3 Selective Estrogen Receptor Modulators
11.2.4 Parathyroid Hormone Therapy
11.2.5 RANK Ligand Inhibitors
11.3 Osteoporosis Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Injectable
11.3.4 Others
11.4 Osteoporosis Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Specialty Clinics
11.4.4 Home Healthcare
11.4.5 Others
11.5 Osteoporosis Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Retail Pharmacies
11.5.4 Online Pharmacies
11.5.5 Others
11.6 Osteoporosis Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
12 United States Cervical Dystonia Market
12.1 Cervical Dystonia Market Historical Value (2017-2023)
12.2 Cervical Dystonia Market Forecast Value (2024-2032)
12.3 Cervical Dystonia Market by Type
12.4 Cervical Dystonia Market by Therapy
13 EU-4 and United Kingdom Cervical Dystonia Market
13.1 Cervical Dystonia Market Historical Value (2017-2023)
13.2 Cervical Dystonia Market Forecast Value (2024-2032)
13.3 Germany Cervical Dystonia Market Overview
13.3.1 Cervical Dystonia Market by Type
13.3.2 Cervical Dystonia Market by Therapy
13.4 France Cervical Dystonia Market Overview
13.4.1 Cervical Dystonia Market by Type
13.4.2 Cervical Dystonia Market by Therapy
13.5 Italy Cervical Dystonia Market Overview
13.5.1 Cervical Dystonia Market by Type
13.5.2 Cervical Dystonia Market by Therapy
13.6 Spain Cervical Dystonia Market Overview
13.6.1 Cervical Dystonia Market by Type
13.6.2 Cervical Dystonia Market by Therapy
13.7 United Kingdom Cervical Dystonia Market Overview
13.7.1 Cervical Dystonia Market by Type
13.7.2 Cervical Dystonia Market by Therapy
14 Japan Cervical Dystonia Market
14.1 Cervical Dystonia Market Historical Value (2017-2023)
14.2 Cervical Dystonia Market Forecast Value (2024-2032)
14.3 Cervical Dystonia Market by Type
14.4 Cervical Dystonia Market by Therapy
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 DAIICHI SANKYO COMPANY
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisition
21.1.5 Certifications
21.2 Amgen Inc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisition
21.2.5 Certifications
21.3 Merck & Co., Inc
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisition
21.3.5 Certifications
21.4 AbbVie Inc
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisition
21.4.5 Certifications
21.5 Bayer AG
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisition
21.5.5 Certifications
21.6 Johnson & Johnson Services, Inc.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisition
21.6.5 Certifications
21.7 Sanofi.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisition
21.7.5 Certifications
21.8 Bristol-Myers Squibb Company
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisition
21.8.5 Certifications
21.9 Takeda Pharmaceutical Company Limited
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisition
21.9.5 Certifications
21.10 Pfizer Inc.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisition
21.10.5 Certifications
21.11 Astrazeneca
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisition
21.11.5 Certifications
21.12 Eli Lilly And Company
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisition
21.12.5 Certifications
21.13 Novartis AG
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisition
21.13.5 Certifications
21.14 F. Hoffmann-La Roche Ltd
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisition
21.14.5 Certifications
21.15 GlaxoSmithKline plc.
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisition
21.15.5 Certifications
22 Osteoporosis Market - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 13.9 billion in 2023, driven by the increasing geriatric population.
The market is anticipated to grow at a CAGR of 3.58% during the forecast period of 2024-2032 and is likely to reach a market value of USD 19.9 billion by 2032.
The growing geriatric population, increasing prevalence of osteoporosis, innovations, technical advancements, government initiatives, clinical trials, and R&D activities are among the major factors driving the market growth.
The market growth is influenced by the approval of new treatment options, such as the approval of a generic version of Forteo in the United States.
The major regions of the market include the United States, EU-4 and the United Kingdom, and Japan. EU-4 is divided into Germany, France, Italy, and Spain.
There are two types of primary osteoporosis and secondary osteoporosis.
The therapies can be divided into bisphosphonates, selective estrogen receptor modulators, parathyroid hormone therapy, and RANK ligand inhibitors.
The routes of administration include oral and injectables, among others.
The distribution channels in the market include hospitals, retail pharmacies, and online pharmacies, among others.
Key players involved in the market are DAIICHI SANKYO COMPANY, Amgen Inc., Merck & Co., Inc, AbbVie Inc, Bayer AG, Johnson & Johnson Services, Inc., Sanofi., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Pfizer Inc., Astrazeneca, Eli Lilly and Company, Novartis AG, GlaxoSmithKline plc., and F. Hoffmann-La Roche Ltd.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER